WANBURY LIMITED Share Price
WANBURY LIMITED Share Price Today
As of 5 Jul 2026, WANBURY LIMITED share price is ₹286.45. The stock opened at ₹289.70, compared to its previous close of ₹286.75. During today's trading session, WANBURY LIMITED share price moved in the range of ₹285.00 to ₹294.00, with an average price of ₹289.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹161.50 and a high of ₹315.20. On the performance front, WANBURY LIMITED share price has increased by 21.37% over the last six months and is up 3.15% on a year-on-year basis.
WANBURY LIMITED Returns Calculator
WANBURY LIMITED Shareholder Returns
WANBURY LIMITED Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
WANBURY LIMITED Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹599.51 | ₹575.65 | ₹499.65 | ₹511.19 |
| Other Income | ₹3.49 | ₹2.99 | ₹0.91 | ₹1.51 |
| Total Revenue | ₹603.01 | ₹578.64 | ₹500.56 | ₹512.69 |
| Total Expenses | ₹573.46 | ₹547.86 | ₹510.25 | ₹507.93 |
| Profit Before Tax | ₹29.55 | ₹56.34 | -₹10.29 | ₹81.13 |
| Tax | -₹0.98 | ₹0.38 | ₹0.11 | -₹0.35 |
| Profit After Tax | ₹30.53 | ₹55.96 | -₹10.40 | ₹81.47 |
| EPS - Basic | ₹9.32 | ₹17.10 | -₹3.18 | ₹25.29 |
| EPS - Diluted | ₹8.98 | ₹16.89 | -₹3.18 | ₹25.21 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹29.55 | ₹56.34 | -₹10.29 | ₹81.13 |
| Income before WC changes | ₹77.53 | ₹72.39 | ₹26.72 | ₹37.45 |
| Change in Assets | -₹30.39 | -₹36.09 | ₹27.33 | -₹60.30 |
| Change in Liabilities | -₹20.66 | -₹32.14 | -₹34.08 | ₹63.54 |
| Change in WC | -₹51.06 | -₹68.23 | -₹6.75 | ₹3.24 |
| Cash flow from Operations | ₹26.10 | ₹3.98 | ₹19.80 | ₹40.52 |
| Cash flow from Investing | -₹51.17 | -₹16.63 | -₹8.84 | ₹0.59 |
| Cash flow from Financing | ₹25.73 | ₹14.55 | -₹31.99 | -₹28.58 |
| Total Cash Flow | ₹0.66 | ₹1.91 | -₹21.03 | ₹12.52 |
| Cash (Start of the year) | ₹3.40 | ₹1.49 | ₹22.53 | ₹10.00 |
| Cash (End of the year) | ₹4.06 | ₹3.40 | ₹1.49 | ₹22.53 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹220.47 | ₹184.21 | ₹181.71 | ₹181.31 |
| Current Assets | ₹193.44 | ₹159.29 | ₹121.81 | ₹171.24 |
| Total Assets | ₹413.92 | ₹343.49 | ₹303.52 | ₹352.55 |
| Current Liabilities | ₹174.61 | ₹214.11 | ₹320.03 | ₹359.77 |
| Net Current Asset | ₹18.83 | -₹54.82 | -₹198.22 | -₹188.53 |
| Non-Current Liabilities | ₹180.03 | ₹101.45 | ₹16.31 | ₹16.20 |
| Equity Capital | ₹59.27 | ₹27.94 | -₹32.82 | -₹23.42 |
| Total Equity & Liabilities | ₹413.92 | ₹343.49 | ₹303.52 | ₹352.55 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹599.51 | ₹577.74 | ₹499.65 | ₹511.19 |
| Other Income | ₹3.49 | ₹0.90 | ₹0.91 | ₹1.51 |
| Total Revenue | ₹603.01 | ₹578.64 | ₹500.56 | ₹512.69 |
| Total Expenses | ₹573.46 | ₹547.86 | ₹510.25 | ₹507.93 |
| Profit Before Tax | ₹29.55 | ₹30.78 | -₹10.29 | ₹81.13 |
| Tax | -₹0.98 | ₹0.38 | ₹0.11 | -₹0.35 |
| Profit After Tax | ₹30.53 | ₹30.40 | -₹10.40 | ₹81.47 |
| EPS - Basic | ₹9.32 | ₹9.29 | -₹3.18 | ₹25.29 |
| EPS - Diluted | ₹8.98 | ₹9.18 | -₹3.18 | ₹25.21 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹29.55 | ₹30.78 | -₹10.29 | ₹81.13 |
| Income before WC changes | ₹77.53 | ₹72.39 | ₹26.72 | ₹37.45 |
| Change in Assets | -₹30.39 | -₹38.45 | ₹27.36 | -₹60.31 |
| Change in Liabilities | -₹20.66 | -₹29.06 | -₹34.11 | ₹63.55 |
| Change in WC | -₹51.06 | -₹67.51 | -₹6.75 | ₹3.24 |
| Cash flow from Operations | ₹26.10 | ₹4.70 | ₹19.80 | ₹40.52 |
| Cash flow from Investing | -₹51.17 | -₹16.63 | -₹8.84 | ₹0.59 |
| Cash flow from Financing | ₹25.73 | ₹13.87 | -₹31.99 | -₹28.58 |
| Total Cash Flow | ₹0.66 | ₹1.94 | -₹21.03 | ₹12.53 |
| Cash (Start of the year) | ₹3.40 | ₹1.46 | ₹22.49 | ₹9.96 |
| Cash (End of the year) | ₹4.06 | ₹3.40 | ₹1.46 | ₹22.49 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹220.47 | ₹184.51 | ₹181.71 | ₹181.31 |
| Current Assets | ₹193.44 | ₹158.61 | ₹120.19 | ₹169.69 |
| Total Assets | ₹413.92 | ₹343.12 | ₹301.90 | ₹351.00 |
| Current Liabilities | ₹174.61 | ₹210.70 | ₹292.84 | ₹332.62 |
| Net Current Asset | ₹18.83 | -₹52.09 | -₹172.66 | -₹162.93 |
| Non-Current Liabilities | ₹180.03 | ₹104.48 | ₹16.31 | ₹16.20 |
| Equity Capital | ₹59.27 | ₹27.94 | -₹7.26 | ₹2.19 |
| Total Equity & Liabilities | ₹413.92 | ₹343.12 | ₹301.90 | ₹351.00 |
About WANBURY LIMITED
Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.
WANBURY LIMITED Financial Highlights
- Revenue: WANBURY LIMITED reported revenue of ₹603.00 crore in FY25 vs ₹578.64 crore in FY24. It showed an increase of 4.21% on a yearly basis.
- Operating Profit: WANBURY LIMITED reported an operating profit of ₹29.55 crore in FY25 vs ₹56.34 crore in FY24. It showed a decrease of 47.55% on a year-on-year basis.
- Net Profit: WANBURY LIMITED reported a net profit of ₹30.53 crore in FY25 vs ₹55.96 crore in FY24. It showed a decrease of 45.44% on a yearly basis.
WANBURY LIMITED Quarterly Result Highlights
- WANBURY LIMITED reported revenue of ₹163.53 crore in Jun 2025, compared with ₹173.84 crore in Mar 2025, representing a decrease of 5.93% on a quarter-on-quarter (QoQ) basis.
- WANBURY LIMITED reported an operating profit of ₹13.61 crore in Jun 2025, compared with ₹19.05 crore in Mar 2025, representing a decrease of 28.56% on a quarter-on-quarter (QoQ) basis.
- WANBURY LIMITED reported a profit of ₹13.49 crore in Jun 2025, compared with ₹20.26 crore in Mar 2025, reflecting a decrease of 33.42% on a QoQ basis.
- The earnings per share (EPS) of WANBURY LIMITED stood at ₹9.32 during Jun 2025.
Similar Stocks
FAQs on WANBURY LIMITED Share Price
What is WANBURY LIMITED share price today?
WANBURY LIMITED share price is ₹286.45 as on 03 Jul, 2026, 15:40 IST.
How has the WANBURY LIMITED share price performed in the past?
In the last 1 year, WANBURY LIMITED delivered a return of 3.15%. The WANBURY LIMITED share price hit a high of ₹315.20 and low of ₹161.50.
How much is the Mutual Fund shareholding in WANBURY LIMITED shares?
The Mutual Fund Shareholding in WANBURY LIMITED was 0.00% at the end of Mar 2026.
What is the the 52-week high and low of WANBURY LIMITED shares ?
The 52-week high and low of WANBURY LIMITED share is ₹315.20 and ₹161.50 as of 03 Jul, 2026.
What is the market cap of WANBURY LIMITED?
The market capitalisation of WANBURY LIMITED is ₹1,002.24 Crores as on 03 Jul, 2026.
What are the stock symbols of WANBURY LIMITED?
The stock symbol of WANBURY LIMITED is WANBURY on the NSE, 524212 on the BSE, and the ISIN is INE107F01022.
What was yesterday's closing price of WANBURY LIMITED shares ?
WANBURY LIMITED shares closed yesterday at ₹286.75 on NSE & ₹286.85 on BSE
How to buy WANBURY LIMITED shares?
To buy WANBURY LIMITED shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy WANBURY LIMITED shares on Holidays?
No, shares of WANBURY LIMITED or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell WANBURY LIMITED shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of WANBURY LIMITED?
The PE and PB ratio of WANBURY LIMITED is 23.32 and 12.94 respectively, as on 03 Jul, 2026, 15:40 IST.